The study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates sustained intraocular pressure reductions and decreased medication dependenceMENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventiona ...

Budget impact analysis published in the Expert Review of Ophthalmology journalMENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis (“BIA”) of the TearCare® System (“TearCare”) for the treatment of MGD-associated dry eye disease (“DED” ...

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis ("BIA") of the TearCare® System ("TearCare") for the treatment of MGD-associated dry eye disease ("DED") in the United States. A BIA estimates the fiscal impact of adopting a new tec ...

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Intereste ...

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.35%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.25, delivering a surprise of 19.35%.Over the last four quarters, the company has surp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share SGHT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro ...

Exhibit 99.1 Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance MENLO PARK, Calif., November 7, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the third quarter ended September 30, 2024, and updated it ...

MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at ...

MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peerreviewed journal Clinical Ophthalmology. Key study findings reported in the study manuscript inc ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $21.4 million, reflecting an 11% sequential growth but a 9% decrease compared to Q2 2023 [22][24] - Surgical Glaucoma revenue was $20.2 million, down 5% year-over-year but up 11% sequentially [22][24] - Dry Eye revenue was $1.1 million, down 46% compared to Q2 2023, primarily due to fewer new accounts and reduced sales infrastructure [22][24] - Gross margin for Q2 2024 was 86%, flat year-over-year, with Surgical Glaucoma gross margin at 88% and Dry Eye gross margin at 46% [23][24] Business Segment Data and Key Metrics Changes - Surgical Glaucoma segment showed sequential growth of 11% in revenue, with increased utilization and accounts ordering products [8][22] - Dry Eye segment faced a significant decline in revenue due to strategic shifts and fewer new accounts [22][23] Market Data and Key Metrics Changes - The company is focused on increasing surgeon utilization and reengaging accounts that decreased orders during the LCD uncertainty period [11][12] - The proposed Medicare payment rules for 2025 could enhance the value proposition for OMNI technology, potentially increasing facility payment rates by approximately $600 or 29% [10][26] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven without raising additional equity capital and is focused on long-term growth opportunities [22][24] - The strategy for the Dry Eye segment is shifting towards achieving fair reimbursement, with a price increase for TearCare expected to impact cash pay volume in the short term [20][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in regaining commercial momentum and achieving double-digit growth in the Surgical Glaucoma segment in the second half of 2024 [26][31] - The company is optimistic about the long-term growth potential in both Surgical Glaucoma and Dry Eye markets, with expectations for strong revenue growth in 2025 [21][27] Other Important Information - The company ended Q2 2024 with $118.2 million in cash and cash equivalents and $35 million in debt, reflecting disciplined cash usage [25] - The company is undergoing a patent infringement case against Alcon, with pending rulings that could impact future financials [25] Q&A Session Summary Question: Potential deceleration in Surgical Glaucoma growth - Management acknowledged the impact of previous LCD proposals on growth but expects to regain double-digit growth in the second half of 2024 due to favorable proposed LCDs [30][31] Question: 2025 growth expectations and cash flow breakeven revenue - Management did not provide specific 2025 guidance but expressed confidence in achieving significant growth and improving cash flow efficiency [32][34] Question: Expectations for cash burn in H2 2024 - Management anticipates continued improvements in cash burn while investing in key business areas [37][38] Question: TearCare claims and adoption rates - Management noted that it is still early in the process of getting claims paid for TearCare, with low volume but positive early responses [42][43] Question: OMNI usage mix and standalone reimbursement - Management estimated that about 85% of procedures are done in combination with cataract surgery, with ongoing efforts to develop the standalone market [46][48] Question: Update on conversations with commercial payers for TearCare - Management reported positive early conversations with payers, driven by strong clinical evidence and economic benefits of TearCare [54][56]